Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
INCY
INCY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INCY News
Incyte Receives EU Approval for Zynyz in New Indication
2d ago
NASDAQ.COM
FDA Rejects Zynyz's Additional Indication Application
3d ago
seekingalpha
Incyte's Zynyz Drug Receives EU Approval for Rare Cancer
3d ago
stocktwits
Zynyz Approved by EU for Advanced SCAC Treatment
4d ago
Newsfilter
Analysis of Growth Drivers in the Biliary Tract Cancer Market
Mar 02 2026
Newsfilter
Positive Opinion for Olumiant in Treating Severe Alopecia Areata in Adolescents
Feb 27 2026
PRnewswire
Olumiant Receives Positive Opinion for Treating Severe Alopecia Areata in Adolescents
Feb 27 2026
Newsfilter
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Yahoo Finance
Alopecia Areata Market Poised for Significant Growth
Feb 19 2026
Newsfilter
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
Feb 17 2026
Newsfilter
Atopic Dermatitis Market Growth Insights
Feb 16 2026
Newsfilter
Mixed Close for US Stocks as Retail Sales Stagnate
Feb 11 2026
NASDAQ.COM
US Retail Sales Weakness Impacts Markets
Feb 10 2026
NASDAQ.COM
Incyte Corporation Q4 2025 Earnings Call Highlights
Feb 10 2026
seekingalpha
Analysis of Significant Stock Movements Among Companies
Feb 10 2026
CNBC
Incyte Reports Q4 Results Below Expectations, Issues Weak 2026 Guidance
Feb 10 2026
seekingalpha
Show More News
